On April 20, 2026, MeiraGTx Holdings plc completed a strategic partnership with Hologen Limited involving a total upfront payment of $200 million for developing gene therapies for Parkinson's and genetic obesity disorders. The agreement includes amendments to existing framework agreements and collaboration for innovative medical devices.